copd-pulmonology-xray-ca0416 The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of ...

With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.

The future of AstraZeneca’s three-in-one inhaler Breztri, which was previously hit with a surprising FDA rejection, was hinging on the outcome of another phase 3 trial. And the results from that trial ...

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s entire ...

(Reuters) - AstraZeneca is eyeing the further growth of its respiratory treatments business as a three-drug inhaler was shown to prevent flare-ups and death in cases of smoker's lung. AstraZeneca said ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BREZTRI AEROSPHERE TM (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (The Hill) — Drugmaker AstraZeneca will cap ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BREZTRI AEROSPHERE TM (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the ...